of the study is to provide descriptive statistics on patterns of prasugrel usage in outpatient settings in France. The aim was to observe if the guidance for the use of Prasugrel from the European label was respected.

This retrospective study was conducted to describe treatment patterns of prasugrel in outpatient settings in France using the IMS Disease Analyzer database, which collects electronic medical records of patients followed by a national representative of 1200 French general practitioners (GPs). Anonymous data are collected prospectively and continuously during each follow-up visit. The study population consisted of patients who had at least 1 prescription of prasugrel in outsetting starting from launch to 3 years post launch. The patients were followed from the date of the first prasugrel prescription recorded in the data base (index date) until they died, changed of GP or reached the end of the study, whichever came first.

In France, the IMS Disease Analyzer included 1.052 patients receiving at least one prescription of prasugrel from January 2010 until October 2012. 85% (n=894) were male (n=894), the mean age was 58.5 years. 5.7% of patients were aged more than 75 years, and 5.0% weighed 60kg or less. Only 0.2% (n=2) had a history of TIA/stroke among this cohort.

Prasugrel was prescribed at a daily maintenance dose of 10mg for 99.8% of patients (1.050 patients). Concomitant medications were usual (aspirin, lipid lowering agents, beta blockers, angiotensin-converting-enzyme (ACE)-inhibitors. 55.1% of patients received an anti-ulcer medication (mainly Proton Pump Inhibitor [PPI). The persistence with prasugrel using the MPR (Medication Possession Ratio) was respectively 60.7% and 63.2% for patients with at 6 months (n=504) and 12 months follow-up (n=213). 13.7% of patients were switched from another thienopyridine (primarily clopidogrel).

In prasugrel-treated patients, respect of Prasugrel indications was highly fulfilled. Almost all patients received aspirin combined to prasugrel. Of note, half of patients were treated with an anti-ulcer medication. The main results reflect a good usage of prasugrel by French GPs, in collaboration with cardiologists, with a satisfying understanding and implementation of the European label, in contrast with recent American registry’s findings.